预混赖脯胰岛素与甘精胰岛素比较治疗2型糖尿病效果的Meta分析精选.pdfVIP

• 2014, 14(12): * 211198 2 h e Cochrane Library 2013 3 PubMedEMbaseClinicalTCBMCNKI WanFang Data 2 RCT2013 10 2 RevMan 5.2 Meta 13 RCT4 557 Meta HbA1cWMD= –0.1895%CI –0.33–0.02P=0.03 WMD=–0.3895%CI –0.52–0.24P0.000 01 FPGWMD=0.8295%CI 0.650.99P0.000 01 WMD=0.6495%CI 0.261.02P=0.000 9WMD=0.93 95%CI 0.311.56P=0.003 WMD=0.7495%CI 0.191.29P=0.009 OR=1.27 95%CI 1.111.45P=0.000 6 OR=2.2495%CI 1.453.46P=0.000 3 2 2 Meta Ef ects of Premixed Insulin Lispro versus Insulin Glargine on Type 2 Diabetes Mellitus: A Meta-Analysis ZHOU Li-li, MA Jun-jie, MA Ai-xia* School of Pharmaceutical International Business, China Pharmaceutical University, Nanjing 211198, China Abstract Objective To systematically review the eicacy and safety of premixed insulin lispro versus insulin glar- gine for type 2 diabetes mellitus (T2DM). Methods Such databases as PubMed, EMbase, h e Cochrane Library (Issue 3, 2013), PubMed, EMbase, ClinicalT, CBM, CNKI and WanFang Data were searched up to October 2013 for rand- omized controlled trials (RCTs) about the clinical eicacy and safety of premixed insulin lispro versus insulin glargine for T2DM. Two reviewers independently screened literature according to the exclusion and inclusion criteria, extracted data, and assessed methodological quality of included studies. h en, meta-analysis was performed using RevMan 5.2 sot ware. Results A total of 13 RCTs involving 4 557 patients were included. h e results of meta-analysis showed that: compared to insulin glargine, premixed insulin lispro was more ef ective in reducing levels of HbA1c (parallel trials: WMD= –0.18,